Novozymes A/S/DKr NSIS B
1D1W1MYTD1Y5YMAX
Capital at risk
About Novozymes A/S
Novozymes A/S is a biotechnology company headquartered in Bagsværd, Denmark, specializing in the production and distribution of enzymes and microbial solutions. The company's core business spans multiple industries, including agriculture, bioenergy, food and beverages, and household care. Novozymes develops essential products such as enzymes for laundry detergents, animal feed additives, and biofuel production aids. Founded in 2000, it originated from a division of the pharmaceutical company Novo Nordisk. The company has a global presence, with significant operations in North America, Europe, and Asia. Novozymes is strategically positioned to capitalize on growing demand for sustainable solutions through its strong commitment to innovation and extensive expertise in biosolutions.
- Ticker
- DKr NSIS B
- Sector
- Materials
- Primary listing
- CSE
- Employees
- 11,098
- Headquarters
- Lyngby, Denmark
- Website
- www.novonesis.com
Novozymes A/S Metrics
BasicAdvanced
kr 199B
42.40
kr 10.12
0.62
kr 6.60
1.54%
Price and volume
Market cap
kr 199B
Beta
0.62
52-week high
kr 465.00
52-week low
kr 336.80
Average daily volume
557K
Dividend rate
kr 6.60
Financial strength
Current ratio
1.738
Quick ratio
1.036
Long term debt to equity
25.38
Total debt to equity
27.507
Dividend payout ratio (TTM)
64.19%
Interest coverage (TTM)
13.94%
Profitability
EBITDA (TTM)
12,031.415
Gross margin (TTM)
56.39%
Net profit margin (TTM)
14.70%
Operating margin (TTM)
23.30%
Effective tax rate (TTM)
21.32%
Revenue per employee (TTM)
kr 2,915,340
Management effectiveness
Return on assets (TTM)
3.79%
Return on equity (TTM)
5.77%
Valuation
Price to earnings (TTM)
42.395
Price to revenue (TTM)
6.231
Price to book
17.9
Price to tangible book (TTM)
5,640.63
Price to free cash flow (TTM)
34.834
Free cash flow yield (TTM)
2.87%
Free cash flow per share (TTM)
12.316
Dividend yield (TTM)
1.54%
Growth
Revenue change (TTM)
4.86%
Earnings per share change (TTM)
-32.02%
3-year revenue growth (CAGR)
21.74%
10-year revenue growth (CAGR)
8.65%
3-year earnings per share growth (CAGR)
-6.42%
10-year earnings per share growth (CAGR)
0.58%
3-year dividend per share growth (CAGR)
3.17%
10-year dividend per share growth (CAGR)
6.57%
Bulls say / Bears say
Novonesis posted 7% organic sales growth in Q1, topping the 6.2% consensus as strong volume in its biosolutions business offset tough comparables. (Reuters)
The Food & Health division grew 9% in Q1 versus a consensus forecast of 6.1%, driven by robust demand for dairy cultures and enzyme solutions. (Reuters)
In April, Novonesis acquired a fermentation facility in Rayong, Thailand for $50 million, expanding its Southeast Asian production capacity to meet rising regional demand. (Reuters)
Novonesis delivered weaker-than-expected 4% organic growth in Q4, falling short of the 5.2% analysts’ consensus, as the Agriculture, Energy & Tech segment saw flat euro sales. (Reuters)
Year-on-year organic growth decelerated to 7% in Q1 from 11% a year earlier, signaling waning demand momentum despite still-robust end markets. (Reuters)
Q1 adjusted EBITDA margin of 37.8% was achieved only after absorbing a “strong currency headwind,” underscoring the vulnerability of profitability to FX fluctuations. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2026.
Upcoming events
No upcoming events
Funds containing Novozymes A/S
AllEURGBPUSD
Fund name | Fund size | DKr NSIS B weighting |
|---|---|---|
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 1.25% |
SPDR MSCI World Materials€WMAT | €198M | 0.76% |
iShares MSCI Europe SRI£IESG | £2.6B | 0.68% |
iShares MSCI Europe SRI€IESE | €3.1B | 0.65% |
iShares MSCI Europe ESG Enhanced€EMNU | €5B | 0.23% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.